Chemerin及ChemR23与糖尿病大血管病变

Chemerin/ChemR23 and Macroangiopathy in Diabetes

Chemerin是2007年新确认的一种脂肪因子,其主要功能受体为ChemR23。近期研究发现chemerin可能是联系肥胖、糖尿病及动脉粥样硬化的潜在因子,有望为糖尿病及其血管并发症的预防及治疗提供新的靶点。然而,chemerin及其受体ChemR23参与糖尿病及其大血管病变的具体机制尚不明确。本文将就目前研究中chemerin及其受体ChemR23与糖尿病及其大血管病变的关系作一综述,并从免疫及炎症反应、氧化应激、自噬、糖脂代谢和胰岛素抵抗等方面,分析chemerin分别对巨噬细胞、血管内皮细胞、脂肪细胞及骨骼肌细胞的影响,从而进一步阐述chemerin及其受体ChemR23参与糖尿病及其大血管病变的具体生物学机制。

Chemerin is a novel adipokine, which is identified in 2007. Its main functional receptor is ChemR23. Recent studies have found that chemerin may be a potential factor linked to obesity, diabetes and atherosclerosis, so it is expected to provide a new target for the prevention and treatment of diabetes and its vascular complications. However, the specific mechanism for chemerin and its receptor ChemR23 involving in diabetes and its vascular complications is not clear so far. This review summarizes the recent findings on the relationship of chemerin/ChemR23 and macroangiopathy in diabetes. Besides, we analysis the role of chemerin on macrophages, endothelial cells, adipocytes and skeletal muscle cells, involving in immune response, inflammation, oxidative stress, autophagy, glycolipid metabolism and insulin resistance to elaborate the related mechanisms.